RCM Technologies Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw strong growth in engineering and healthcare, with record backlog for 2026 and robust client expansion. Despite excess medical costs and some segment margin variability, momentum remains high heading into Q4 and 2026, supported by digital innovation and active capital management.
-
Q2 2025 saw record gross profit and double-digit growth in adjusted EBITDA and EPS, driven by strong performance in healthcare, engineering, and aerospace. The company anticipates continued growth, a robust balance sheet, and is evaluating a potential dividend.
-
Q1 2025 saw record gross profit and strong growth in adjusted EBITDA and EPS, with robust performance across healthcare, engineering, and aerospace segments. Share repurchases and debt reduction enhanced financial flexibility, and management expects continued double-digit EBITDA growth in 2025.
Fiscal Year 2024
-
Q4 2024 saw flat gross profit and lower adjusted EBITDA due to one-time costs, but underlying business momentum remains strong with growth in healthcare, new contracts, and improved DSOs. Management targets double-digit adjusted EBITDA growth in 2025 and expects tax rates to normalize.
-
Q3 saw solid growth in healthcare and engineering, with gross profit and Adjusted EBITDA both rising year-over-year. Management expects continued double-digit earnings growth, strong cash flow, and record performance in 2025, supported by robust demand and disciplined capital allocation.
-
Q2 2024 saw strong growth in engineering and school-based healthcare, with gross profit up 6.6% and adjusted EBITDA up 10.8% year-over-year. The outlook remains positive, with a record pipeline of new school contracts and continued investments in technology and international expansion.